Guillain-Barré Syndrome
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chugai PharmaCrovalimab
Annexon BiosciencesANX005
Clinical Trials (2)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
Start: Nov 2022Est. completion: Sep 20260
Phase 3Withdrawn
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
Start: Jan 2020Est. completion: May 2021
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space